Derbend Asset Management Crispr Therapeutics Ag Transaction History
Derbend Asset Management
- $200 Million
- Q1 2024
A detailed history of Derbend Asset Management transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Derbend Asset Management holds 3,673 shares of CRSP stock, worth $149,564. This represents 0.13% of its overall portfolio holdings.
Number of Shares
3,673
Previous 3,753
2.13%
Holding current value
$149,564
Previous $234,000
6.84%
% of portfolio
0.13%
Previous 0.14%
Shares
8 transactions
Others Institutions Holding CRSP
# of Institutions
490Shares Held
58MCall Options Held
1.1MPut Options Held
1.9M-
Capital International Investors Los Angeles, CA7.93MShares$323 Million0.07% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl7.5MShares$305 Million3.35% of portfolio
-
State Street Corp Boston, MA2.99MShares$122 Million0.01% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.2.97MShares$121 Million0.1% of portfolio
-
Nikko Asset Management Americas, Inc.2.97MShares$121 Million1.61% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $3.18B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....